Skip to main content
Clinical Trials/NCT01176825
NCT01176825
Completed
Phase 1

Reducing High-Risk Behaviors Among Bipolar Patients Transitioning to Adulthood

Massachusetts General Hospital1 site in 1 country55 target enrollmentSeptember 2007

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Bipolar Disorder
Sponsor
Massachusetts General Hospital
Enrollment
55
Locations
1
Primary Endpoint
Clinical Global Improvement Scale (CGI)-Improvement
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The aim of the study is to develop and pilot test a cognitive-behavioral (CBT) intervention for young adults, ages 18-24 with bipolar disorder. The 14-week intervention focuses on improving management of bipolar disorder, reducing involvement in high-risk behaviors, and enhancing psychosocial functioning. The intervention also focuses on issues specific to transition-age youth. The study includes two phases: In phase 1, the intervention will be developed, refined, and openly piloted with several participants. In phase 2,the investigators will conduct a randomized clinical trial, in which 40 participants will be randomized either to receive the intervention right away, or to a 14-week waitlist condition. Participants will be evaluated at baseline, week 5, week 10, and week 14 of the study period, as well as at 3- and 6-month follow up, using measures of mood symptoms, high-risk behaviors, drug and alcohol use, and psychosocial functioning.

Registry
clinicaltrials.gov
Start Date
September 2007
End Date
November 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Aude Henin

Co-Director, Child CBT Program

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • diagnosis of bipolar spectrum disorder (Bipolar I, Bipolar II, or Bipolar NOS Disorder)
  • ages 18-24 years
  • able to understand the nature of the study as well as potential risks and benefits
  • in treatment with a physician or nurse-practitioner for their bipolar disorder, or willing to seek and obtain such treatment if needed.

Exclusion Criteria

  • concurrent cognitive-behavioral psychotherapy
  • documented mental retardation
  • pervasive developmental disorder
  • current serious medical illness
  • inability to participate in the intervention because of acuity of symptoms
  • current drug or alcohol dependence (other than marijuana dependence)

Outcomes

Primary Outcomes

Clinical Global Improvement Scale (CGI)-Improvement

Time Frame: week 5, week 10, week 14, 3 mo fu, 6 mo fu

Clinician-rated change in mood symptoms and overall functioning

feasibility and acceptability

Time Frame: post-treatment

We will assess the percentage of completers versus drop-outs to examine feasibility of treatment procedures

Secondary Outcomes

  • Self-Control Behavior Schedule(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Adapted Y-BOCS(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Timeline Follow-Back(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Medication history and adherence(baseline, post-treatment, 6 month follow-up)
  • High-Risk Sexual Behaviors(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Beck Hopelessness Scale(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Social Adjustment Scale (SAS)(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Barratt Impulsiveness Scale(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Young Mania Rating Scale(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • SCID depression and mania modules(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Adult Suicidal Ideation Questionnaire (ASIQ)(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Hamilton Depression Scale (HAM-D)(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Risky Driving Inventory(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Treatment Satisfaction Questionnaire(post-treatment)
  • South Oaks Gambling Screen(baseline, week 5, week 10, week 14, 3 mo fu, 6 mo fu)
  • Urine Toxicology Screen(baseline, post-treatment, 6 mo follow-up)

Study Sites (1)

Loading locations...

Similar Trials